Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ckj/sfv044 http://scihub22266oqcxt.onion/10.1093/ckj/sfv044 26251714!4515899!26251714     free     free     free       Clin+Kidney+J 2015 ; 8 (4): 445-8 Nephropedia Template TP {{tp|p=26251714|t=2015. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis |pdf=|usr=}}{{26251714}} gab.com Text Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis JO: Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=26251714 #FOAvip C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal immunoglobulin deposition caused by alternative complement pathway dysregulation. Unfortunately, no therapeutic intervention has consistently improved outcomes for patients with C3G. Eculizumab, a monoclonal antibody to C5, is currently the only approved complement-specific agent with some efficacy in the treatment of C3 glomerulonephritis (C3GN). Here, we describe a patient with acute crescentic C3GN with no identified complement mutation or family history of renal disease who required dialysis for 6 months. Five months after initiation of eculizumab, she became dialysis independent, showing improvement is possible after adequate time on eculizumab. Twit Text FOAVip Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis ????Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=26251714 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26251714 #FOAvip English Wikipedia <ref>{{Cite pmid|26251714}}</ref> Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis #MMPMID26251714 Inman M; Prater G; Fatima H; Wallace E Clin Kidney J 2015[Aug]; 8 (4): 445-8 PMID26251714show ga C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal immunoglobulin deposition caused by alternative complement pathway dysregulation. Unfortunately, no therapeutic intervention has consistently improved outcomes for patients with C3G. Eculizumab, a monoclonal antibody to C5, is currently the only approved complement-specific agent with some efficacy in the treatment of C3 glomerulonephritis (C3GN). Here, we describe a patient with acute crescentic C3GN with no identified complement mutation or family history of renal disease who required dialysis for 6 months. Five months after initiation of eculizumab, she became dialysis independent, showing improvement is possible after adequate time on eculizumab. ?Eculizumab-induced reversal of dialysis-dependent kidney failure from (epmc).pdf DeepDyve Pubget Overpricing